These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23763844)

  • 1. Cost-effectiveness of continuous-flow left ventricular assist devices.
    Neyt M; Van den Bruel A; Smit Y; De Jonge N; Erasmus M; Van Dijk D; Vlayen J
    Int J Technol Assess Health Care; 2013 Jul; 29(3):254-60. PubMed ID: 23763844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy.
    Rogers JG; Bostic RR; Tong KB; Adamson R; Russo M; Slaughter MS
    Circ Heart Fail; 2012 Jan; 5(1):10-6. PubMed ID: 22052901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left Ventricular Assist Devices for Destination Therapy: A Health Technology Assessment.
    Health Quality Ontario
    Ont Health Technol Assess Ser; 2016; 16(3):1-60. PubMed ID: 27026798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic Evaluation of Left Ventricular Assist Devices for Patients With End Stage Heart Failure Who Are Ineligible for Cardiac Transplantation.
    Chew DS; Manns B; Miller RJH; Sharma N; Exner DV
    Can J Cardiol; 2017 Oct; 33(10):1283-1291. PubMed ID: 28941608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cost-utility of left ventricular assist devices for end-stage heart failure patients ineligible for cardiac transplantation: a systematic review and critical appraisal of economic evaluations.
    Neyt M; Van den Bruel A; Smit Y; De Jonge N; Vlayen J
    Ann Cardiothorac Surg; 2014 Sep; 3(5):439-49. PubMed ID: 25452904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure.
    Long EF; Swain GW; Mangi AA
    Circ Heart Fail; 2014 May; 7(3):470-8. PubMed ID: 24563450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluation.
    Clegg AJ; Scott DA; Loveman E; Colquitt J; Hutchinson J; Royle P; Bryant J
    Health Technol Assess; 2005 Nov; 9(45):1-132, iii-iv. PubMed ID: 16303098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and cost-effectiveness of left ventricular assist devices as destination therapy for advanced heart failure: systematic review and economic evaluation.
    Beese S; Avşar TS; Price M; Quinn D; Lim HS; Dretzke J; Ogwulu CO; Barton P; Jackson L; Moore D
    Health Technol Assess; 2024 Aug; 28(38):1-237. PubMed ID: 39189844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of the implantable HeartMate II left ventricular assist device for patients awaiting heart transplantation.
    Moreno SG; Novielli N; Cooper NJ
    J Heart Lung Transplant; 2012 May; 31(5):450-8. PubMed ID: 22115674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables.
    John R; Pagani FD; Naka Y; Boyle A; Conte JV; Russell SD; Klodell CT; Milano CA; Rogers J; Farrar DJ; Frazier OH
    J Thorac Cardiovasc Surg; 2010 Jul; 140(1):174-81. PubMed ID: 20447659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure.
    Baras Shreibati J; Goldhaber-Fiebert JD; Banerjee D; Owens DK; Hlatky MA
    JACC Heart Fail; 2017 Feb; 5(2):110-119. PubMed ID: 28017351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical and cost-effectiveness analysis of the HeartMate 3 left ventricular assist device for transplant-ineligible patients: A United Kingdom perspective.
    Lim HS; Shaw S; Carter AW; Jayawardana S; Mossialos E; Mehra MR
    J Heart Lung Transplant; 2022 Feb; 41(2):174-186. PubMed ID: 34922821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of left ventricular assist devices (LVADs) for patients with advanced heart failure: analysis of the British NHS bridge to transplant (BTT) program.
    Clarke A; Pulikottil-Jacob R; Connock M; Suri G; Kandala NB; Maheswaran H; Banner NR; Sutcliffe P
    Int J Cardiol; 2014 Feb; 171(3):338-45. PubMed ID: 24424339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurocognitive function in destination therapy patients receiving continuous-flow vs pulsatile-flow left ventricular assist device support.
    Petrucci RJ; Rogers JG; Blue L; Gallagher C; Russell SD; Dordunoo D; Jaski BE; Chillcott S; Sun B; Yanssens TL; Tatooles A; Koundakjian L; Farrar DJ; Slaughter MS
    J Heart Lung Transplant; 2012 Jan; 31(1):27-36. PubMed ID: 22153550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.
    John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L
    Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device.
    Pagani FD; Miller LW; Russell SD; Aaronson KD; John R; Boyle AJ; Conte JV; Bogaev RC; MacGillivray TE; Naka Y; Mancini D; Massey HT; Chen L; Klodell CT; Aranda JM; Moazami N; Ewald GA; Farrar DJ; Frazier OH;
    J Am Coll Cardiol; 2009 Jul; 54(4):312-21. PubMed ID: 19608028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.
    Lietz K; Long JW; Kfoury AG; Slaughter MS; Silver MA; Milano CA; Rogers JG; Naka Y; Mancini D; Miller LW
    Circulation; 2007 Jul; 116(5):497-505. PubMed ID: 17638928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of left ventricular assist devices for patients with end-stage heart failure: analysis of the French hospital discharge database.
    Tadmouri A; Blomkvist J; Landais C; Seymour J; Azmoun A
    ESC Heart Fail; 2018 Feb; 5(1):75-86. PubMed ID: 28741873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. End-organ function in patients on long-term circulatory support with continuous- or pulsatile-flow assist devices.
    Radovancevic B; Vrtovec B; de Kort E; Radovancevic R; Gregoric ID; Frazier OH
    J Heart Lung Transplant; 2007 Aug; 26(8):815-8. PubMed ID: 17692785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term continuous flow left ventricular assist device support and end-organ function: prospects for destination therapy.
    Slaughter MS
    J Card Surg; 2010 Jul; 25(4):490-4. PubMed ID: 20642766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.